[Strongyloides stercoralis infection in patients with bronchial obstructive pathology].
Strongyloides stercoralis infection was hardly seen in Spain until a few years ago but has recently been shown to be fairly common in some geographic areas. In the respiratory tract this germ can cause acute bronchospasms that make diagnosis difficult, particularly in patients with underlying bronchial disease. To determine if curing S. stercoralis infection is accompanied by clinical and functional improvement in patients with bronchial obstruction, we studied the evolution of 22 infected patients: 11 with no bronchopulmonary disease and 11 with chronic airway obstruction or asthma. The following variables were assessed in both groups at the moment of diagnosis of infection and four months after cure: levels of eosinophils and total serum IgE, respiratory symptoms, steroid doses and spirometric parameters. After four months we observed a significant decrease in eosinophil (16 versus 5%) and IgE (1,600 versus 770 IU/ml) levels in both groups. The number of bronchospasms and daily steroid doses required decreased in the group with bronchial disease. No significant differences were seen in spirometric parameters, however. The improvement in respiratory symptoms, blood parameters and need for medication leads us to believe that airway inflammation decreases after the infection has been eradicated, in spite of the lack of improvement in bronchial obstruction.
Cremades Romero
M J
MJ
Servicio de Neumología, Hospital Universitario La Fe, Valencia.
Pellicer Ciscar
C
C
Menéndez Villanueva
R
R
Ricart Olmos
C
C
Pastor-Guzmán
A
A
Estellés Piera
F
F
Igual Adell
R
R
Gilabert Bonet
M J
MJ
D000368:Aged; D000818:Animals; D000969:Antinematodal Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies; D017171:Strongyloides stercoralis; D013322:Strongyloidiasis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013827:Thiabendazole / Q000627:therapeutic use
D000969:Antinematodal Agents; D013827:Thiabendazole